title: Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
abstract: BACKGROUND
  Triple therapy with proton pump inhibitor, clarithromycin and amoxicillin and, in the event of eradication failure, quadruple therapy with proton pump inhibitor, bismuth, tetracycline and metronidazole have been proposed in Maastricht as the optimal sequential treatment of Helicobacter pylori infection.
  
  
  OBJECTIVE
  To compare two second-line regimens with quadruple therapy.
  
  
  METHODS
  One hundred and eighty patients with a previous failed course of standard therapy were randomly given one of the following 7-day treatments: ranitidine bismuth citrate 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d. (RBCAT), pantoprazole 40 mg b.d. plus amoxicillin 1 g b.d. and levofloxacin 500 mg/day (PAL) and pantoprazole 40 mg b.d., bismuth citrate 240 mg b.d., tetracycline 500 mg q.d.s. and metronidazole 500 mg b.d. (PBTM). The eradication rate was assessed by 13C-urea breath test. Side-effects and compliance were evaluated by a standardized questionnaire and by counting returned medication.
  
  
  RESULTS
  The RBCAT, PAL and PBTM groups achieved mean intention-to-treat eradication rates of 85%, 63% and 83%, respectively (P<0.05 for PAL vs. either RBCAT or PBTM). Compliance was optimal in all patients, although side-effects were more commonly observed in the PBTM group than in the other two patient groups (P<0.0001).
  
  
  CONCLUSIONS
  Both RBCAT and PBTM can be used as second-line therapies. Conversely, PAL did not achieve satisfactory eradication rates.
authors.affiliation: Division of Gastroenterology, Hospital, IRCCS, San Giovanni Rotondo, Italy. f.perri@operapadrepio.it
authors.forename: F
authors.initials: F
authors.lastname: Perri
authors.forename: V
authors.initials: V
authors.lastname: Festa
authors.forename: A
authors.initials: A
authors.lastname: Merla
authors.forename: F
authors.initials: F
authors.lastname: Barberani
authors.forename: A
authors.initials: A
authors.lastname: Pilotto
authors.forename: A
authors.initials: A
authors.lastname: Andriulli
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage; D001729:Bismuth / Q000008:administration & dosage; D001944:Breath Tests; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008795:Metronidazole / Q000008:administration & dosage; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage; D009853:Omeprazole / Q000031:analogs & derivatives; D000077402:Pantoprazole; D011446:Prospective Studies; D011899:Ranitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013454:Sulfoxides / Q000008:administration & dosage; D014011:Tinidazole / Q000008:administration & dosage; D017211:Treatment Failure; D014508:Urea / Q000032:analysis
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000890:Anti-Infective Agents; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D014011:Tinidazole; D008795:Metronidazole; D064704:Levofloxacin; C073340:ranitidine bismuth citrate; D000658:Amoxicillin; D011899:Ranitidine; D014508:Urea; D015242:Ofloxacin; D000077402:Pantoprazole; D009853:Omeprazole; D001729:Bismuth